Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Battaglini (Genova, Italy), G. Li Bassi (Barcelona, Spain), F. Pagliara (Genova, Italy), A. Meli (Milano, Italy), H. Yang (Barcelona, Spain), M. Yang (Barcelona, Spain), A. Motos (Barcelona, Spain), J. Bobi (Barcelona, Spain), E. Aguilera (Barcelona, Spain), T. Senussi (Genova, Spain), J. Miller (Barcelona, Spain), L. Fernandez (Barcelona, Spain), E. Barbeta Viñas (Barcelona, Spain), A. Torres (Barcelona, Spain). Telavancin vs. linezolid in an animal model of severe MRSA pneumonia. 5457

Member's Comments

No comment yet.

Related content which might interest you: Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006 Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004 New antibiotics for VAP Source: Eur Respir Mon 2011; 53: 48-53 Year: 2011 Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 What is MRSA? Source: Eur Respir J 2009; 34: 1190-1196 Year: 2009 Clinical outcomes of patients with hospital-acquired pneumonia due to community-associated methicillin resistant staphylococcus aureus (CA-MRSA) Source: Eur Respir J 2007; 30: Suppl. 51, 407s Year: 2007 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Community-acquired pneumonia outbreaks control with azithromycin Source: Eur Respir J 2003; 22: Suppl. 45, 148s Year: 2003 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004 Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009 Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006